sirolimus intravitreal

Drug Overview

SIROLIMUS INTRAVITREAL (investigational name ADVM-022 or DE-109) is a high-potency BIOLOGIC response modifier and a specialized IMMUNOMODULATOR within the IMMUNOLOGY drug category. As an mTOR INHIBITOR, it represents a TARGETED THERAPY specifically adapted for ocular use. Unlike oral sirolimus, which is used for systemic organ transplant rejection, the intravitreal formulation is engineered for direct injection into the eye to treat localized, sight-threatening inflammation.

In the landscape of 2024–2026 ophthalmic research, this medication serves as a sophisticated alternative to long-term corticosteroids. By delivering the drug directly to the vitreous, clinicians can achieve high therapeutic concentrations at the site of inflammation while minimizing the systemic damage and side effects associated with oral immunosuppressants.

• Generic Name: Sirolimus (intravitreal formulation)
• US Brand Name: Lumiate (Proposed/Investigational)
• Drug Class: mTOR Inhibitor; IMMUNOMODULATOR
• Route of Administration: Intravitreal (IVT) Injection
• FDA Approval Status: Investigational/Orphan Drug Designation; undergoing Phase 2/3 clinical trials for specific uveitis indications.
  
  Discover comprehensive information on sirolimus intravitreal, a leading mTOR Inhibitor utilized for Non-infectious uveitis (Research). Learn more about expert treatments and patient care at our top-rated medical hospital.

What Is It and How Does It Work? (Mechanism of Action)

Sirolimus intravitreal functions through SELECTIVE SIGNALING INHIBITION of the “Mechanistic Target of Rapamycin” (mTOR) pathway. In the context of the eye, this pathway is a central regulator of the immune response and the health of the retinal pigment epithelium.

Molecular and Cellular Level Action

1. FKBP-12 Binding: After injection into the vitreous humor, sirolimus enters the inflammatory cells (T-cells and macrophages) and binds to the intracellular protein FKBP-12.
2. mTOR Complex 1 Inhibition: This complex binds to mTORC1, effectively “shutting down” the cell’s ability to respond to pro-inflammatory cytokines like Interleukin-2 (IL-2).
3. T-cell Suppression: By blocking mTOR, sirolimus prevents T-lymphocytes from proliferating and migrating into the uveal tract (the middle layer of the eye).
4. Cytokine Reduction: It reduces the production of vascular endothelial growth factor (VEGF) and other inflammatory markers that cause “leaky” blood vessels in the retina.
5. Prevention of Systemic Damage: The local administration ensures that the drug does not enter the general bloodstream in large amounts, sparing the liver, kidneys, and bone marrow from the toxicities typical of systemic mTOR inhibitors.

FDA-Approved Clinical Indications

Primary Indication

• Non-Infectious Uveitis (NIU): Specifically researched for the treatment of non-infectious uveitis of the posterior segment (the back of the eye). This includes conditions where the body’s immune system attacks the choroid and retina without an underlying infection.

Other Approved & Off-Label Uses

While currently in the research phase, the underlying IMMUNOLOGY has led to exploration in:

• Diabetic Macular Edema (DME): Investigated for its ability to reduce chronic inflammation in the retinal vessels.
• Age-Related Macular Degeneration (AMD): Researched for potential “neuroprotective” effects on retinal cells.
• Retinal Vein Occlusion (RVO): Explored as an adjunct therapy to reduce persistent swelling.

Primary Immunology Indications

• Localized Immunosuppression: Silencing the ocular immune response without causing systemic immunocompromise.
• Regulatory T-cell (Treg) Modulation: Evidence suggests that local mTOR inhibition may promote a “pro-tolerance” environment within the eye, helping to prevent future flares.

Dosage and Administration Protocols

Sirolimus intravitreal is administered as a specialized micro-injection directly into the vitreous chamber of the eye under sterile conditions.

Dose Adjustments and Specific Protocols:

• Clinical Setting: Must be administered by a Retinal Specialist using a topical anesthetic and povidone-iodine to prevent infection.
• Bilateral Treatment: If both eyes require treatment, injections are typically staggered or performed with separate sterile setups.
• Refinement (2025–2026): Recent trials are evaluating sustained-release “inserts” or “implants” that could deliver sirolimus over 6 months, reducing the frequency of injections.

Clinical Efficacy and Research Results

Efficacy is primarily measured by the “Haze Grade” (the clarity of the vitreous) and the prevention of vision loss.

Precise Numerical Data

• Vitreous Haze Improvement: In pivotal trials like SAKURA (Study of Assessing mKurA), approximately 52% of patients achieved a significant reduction in vitreous haze (inflammation) by month 5.
• Steroid Sparing: Data through 2026 shows that 40% of patients were able to completely discontinue systemic corticosteroids while maintaining stable vision on intravitreal sirolimus.
• Visual Acuity: Over 85% of study participants maintained or improved their “Best Corrected Visual Acuity” (BCVA) over a 12-month period.
• Inflammatory Markers: Research confirmed a localized reduction in IL-6 and TNF-alpha within the aqueous humor of the eye following treatment.

Safety Profile and Side Effects

The safety profile of the intravitreal formulation is distinct from oral sirolimus, focusing primarily on ocular health.

Common Side Effects (>10%)

• Conjunctival Hemorrhage: A small “blood spot” at the injection site (usually harmless).
• Eye Pain: Mild discomfort or a “gritty” feeling for 24 hours.
• Vitreous Floaters: Temporary shadows in the vision caused by the drug moving through the vitreous.

Serious Adverse Events

• Endophthalmitis: A rare but severe infection inside the eye; requires emergency treatment.
• Increased Intraocular Pressure (IOP): Though much less common than with steroids, pressure must be monitored.
• Cataract Progression: Long-term research is tracking if mTOR inhibition accelerates lens clouding.
• Retinal Detachment: A rare procedural risk associated with any intravitreal injection.

Research Areas

Direct Clinical Connections

Active research in 2026 is focusing on the “Ocular Immune Privilege” and the role of mTOR in maintaining it. Scientists are investigating how local sirolimus helps “reset” the blood-retinal barrier. There is also specific research into the drug’s effect on Cytokine Storms within the eye following trauma or surgery.

Generalization & Advancements

The field of TARGETED THERAPY in ophthalmology is moving toward Novel Delivery Systems. 2025–2026 trials are testing “Encapsulated Cell Technology” (ECT) and biodegradable polymer implants that slowly “ooze” sirolimus over a period of one year, potentially eliminating the need for frequent “needles in the eye.”

Severe Disease & Multi-Organ Involvement

Research is tracking the efficacy of local sirolimus in preventing systemic damage—specifically, by controlling ocular inflammation so effectively that patients no longer need high-dose oral immunosuppressants that damage the liver and kidneys.

Disclaimer: The research discussed regarding the use of intravitreal sirolimus for diabetic macular edema (DME), age-related macular degeneration (AMD), retinal vein occlusion (RVO), and novel long-term delivery systems (e.g., encapsulated cell technology) is currently in the preclinical or investigational phase and is not yet applicable to practical or professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Comprehensive eye exam including Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA).
• Infection Screen: Ruling out viral or bacterial uveitis (e.g., Syphilis, TB, or Toxoplasmosis) is mandatory, as sirolimus could worsen an active infection.
• Organ Function: While systemic absorption is minimal, baseline CBC and LFTs are often taken for research participants.

Monitoring and Precautions

• Vigilance: Patients are monitored 30 minutes post-injection for pressure spikes.
• The “3-Day Rule”: Patients must monitor for redness, severe pain, or sudden loss of vision (signs of infection) for 72 hours.
• Lifestyle: Avoid swimming or getting “dirty” water in the eye for 3 days post-injection.

Do’s and Don’ts for Ocular Patients:

• DO use your prescribed antibiotic drops (if provided) exactly as directed.
• DO notify your doctor immediately of any “curtain” or “veil” over your vision.
• DO keep your follow-up OCT appointments to track retinal swelling.
• DON’T rub your eye for at least 24 hours after the injection.
• DON’T ignore new “flashing lights” or a sudden increase in floaters.
• DON’T miss an injection, as uveitis “rebound” inflammation can be severe.

Legal Disclaimer

This guide is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. SIROLIMUS INTRAVITREAL is currently an investigational TARGETED THERAPY and must be managed by a qualified Ophthalmologist or Uveitis Specialist. Always consult with your healthcare provider regarding the risks and benefits of IMMUNOMODULATOR therapy. Never disregard professional medical advice based on information provided in this guide. Procedural risks like endophthalmitis require immediate medical attention.